
China is catching up to the US in brain tech, rivaling firms like Elon Musk's Neuralink
The demonstration, captured on video in March by Beijing Radio and Television Station, was part of a clinical trial involving five patients implanted with a coin-sized chip called Beinao-1, a wireless so-called brain computer interface (BCI) – a technology led by scientists in the US, but in which experts say China is quickly catching up.
Luo Minmin, director of the Chinese Institute for Brain Research (CIBR) and the chief scientist behind the trial, said there was a 'very strong' need for BCI technology, saying they had been 'overwhelmed' by requests from potential patients.
'The patients were saying that this feels so great, like they can gain or regain the control of (their) muscles,' he told CNN in May during a rare interview at his lab, located an hour's drive away from Beijing Xuanwu Hospital, where the trial took place.
Luo said the technology was showing 'high accuracy' in decoding signals from the brains of patients and translating the signals into text speech or machine movements. His team is planning to speed up human trials by implanting chips into 50 to 100 more patients over the next year.
'We are hoping that we can move this process faster,' he said. 'If it's proven to be safe and effective … it can be used clinically across the world.'
As of May, Beinao-1 says a total of five patients, the same number as Elon Musk's Neuralink, has its implants. Another US company Synchron, whose investors include Jeff Bezos and Bill Gates, has undergone trials with 10 patients, six in the United States and four in Australia.
Maximilian Riesenhuber, a professor of neuroscience at Georgetown University who was not involved in the Beinao trials, told CNN that despite starting later than the US, China is making advances.
'China has definitely shown the ability to not just catch up, but also then be competitive, and now actually to start, also to drive the field in some areas,' he said. 'Excitingly, there's a lot of research activities in both countries, because they've realized the potential in BCI.'
According to Precedence Research, a market research firm, the market for brain technology was worth about $2.6 billion last year and is expected to rise to $12.4 billion by 2034. But for both China and the US, this technology is about much more than cash.
Chinese leader Xi Jinping has long aimed to turn his country into a science and economic powerhouse. In March, he wrote in state-owned media that the tech industry had become the 'forefront' and 'main battlefield' of global competition. His ambitions have sparked concern in the US, resulting in an ongoing tech war, particularly in the semiconductor industry.
CIBR was jointly founded by the Beijing municipal government and several local universities in 2018, about two years after Elon Musk founded Neuralink near San Francisco.
In 2023, CIBR incubated a private company named NeuCyber NeuroTech to focus on brain tech products such as Beinao-1. Luo, who is also the startup's chief scientist, gave CNN rare access to the institute in May.
For years, he said, the ALS patient, who is in her 60s, was unable to express herself.
'She's awake, she knows what she wants but she could not speak out,' said the scientist, who got his PhD in neuroscience from the University of Pennsylvania and spent nearly a decade in the US. 'Following the implantation, she can now speak simple sentences quite accurately via the system.'
All BCI researchers must address the balance between risk and effectiveness.
Riensenhuber said most American firms use the more invasive method to place chips inside the dura mater, an outer layer of tissue that covers and protects the brain and spinal cord, in order to capture better signal. But these methods require riskier surgeries.
'It is interesting to see that NeuCyber is apparently able to get enough information even through the dura to allow the decoding of specific words,' he said.
The test on the ALS patient, which began in March, marked the Beinao-1 chip's third trial in humans. Those trials made up what the developers described in a press release as 'the world's first batch of semi-invasive implantation of wireless BCI in human brains.' As of May, two more trials have been conducted, for a total of five.
Amid rising geopolitical tensions, comparisons between US and Chinese tech breakthroughs are common. Brain computer interface technology first started in the 1970s in the US.
Decades later, the Obama Administration launched its 'Brain Initiative' in 2013, investing more than $3 billion to fund over a thousand neuroscience technology projects since, according to the National Institute of Health.
Synchron, based in New York, was the first firm to start human trials in July 2021. Three years later, a new BCI system developed at UC Davis Health translated the brain signals of an ALS patient into speech, achieving an accuracy of 97% – the most accurate system of its kind, the university said in a statement. The same year, Musk's company completed its first human trial, enabling the participant to control a computer mouse with a brain implant.
China got its start in brain tech only in the 1990s, but it's advancing fast. In 2014, Chinese scientists introduced the idea of a national project on brain tech to match similar efforts in the US and Europe, according to the Ministry of Science and Technology. Two years later, brain tech was mentioned in the country's five-year plan, which outlines China's national priorities and goals.
'Brain science is new in China,' said Lily Lin, a former research assistant at one of China's top neuroscience research units from 2021 to 2023. 'So, it started a bit late, but its speed of development has been faster than other countries. And the country has given a lot of funding to many scientific research units, and this funding is increasing every year.'
Last year, the government issued its first ethical guidelines for research in this area. At the local level, municipal governments in Beijing, Shanghai and other major cities have also offered support for brain technology companies from research and clinical trials to commercialization.
Riesenhuber and other researchers from Georgetown University published research on China's BCI development in 2024, stating that efforts from Chinese researchers were 'comparable in sophistication' to those in the US and the United Kingdom.
'We found China's non-invasive BCI research to be comparable with that of other scientifically advanced nations and to be working to overcome obstacles to greater fidelity, throughput, and wider use,' according to the issue brief. 'China's invasive BCI research, while historically behind its non-invasive efforts, has picked up the pace and is approaching global standards of sophistication.'
Luo, who has worked in both countries, says the US is the 'front-runner' in both invasive and non-invasive brain tech. But, comparing Beinao-1 and Neuralink is like looking at 'apples and oranges,' he added.
The two systems differ not only in implant location but also in the type of brain signals recorded, as well as the method of data transmission. The Chinese chip records a wider range of brain areas, with lower precision for each neuron.
'All in all, I don't think these two products are in a competitive or exclusive relationship,' Luo added. 'The jury is still out, and we don't know yet which route will ultimately benefit patients better.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why This Analyst Says Amazon Stock Is Still His ‘Top Pick'
Large-cap tech stocks have rebounded strongly from their April lows as easing tariff concerns and a more stable macroeconomic outlook reignite investor confidence. Among these giants, e-commerce and cloud titan Amazon (AMZN) continues to attract bullish sentiment, with analysts reaffirming its long-term growth potential. Morgan Stanley's senior analyst Brian Nowak recently reiterated Amazon as his 'top pick,' raising the stock's price target to $300 from $250, a 20% upward revision. In an accompanying research note, the firm cited a 'more manageable tariff and geopolitical backdrop' alongside improving macro conditions as key reasons for its renewed optimism on AMZN stock. More News from Barchart This Penny Stock Wants to Become the MicroStrategy of Dogecoin Opendoor Stock Is Surging Higher in a Frenzied Retail Rally. How Should You Play OPEN Shares Here? Robinhood Stock Stumbles as S&P 500 Inclusion Is Once Again Off the Table for HOOD Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. In short, the easing of trade tensions and brighter global growth prospects have allowed Morgan Stanley to discard previous worst-case scenarios, such as steep China tariffs, and upgrade its earnings outlook. Crucially, the firm also pointed to accelerating momentum in Amazon Web Services (AWS), fueled by rising demand for artificial intelligence (AI) and cloud-based solutions. With that in mind, let's take a closer look at the specific areas Morgan Stanley believes will drive Amazon's next phase of growth. About Amazon Stock Headquartered in Seattle, Amazon is an e-commerce behemoth that's engaged in online retail, cloud computing, digital streaming, and AI businesses. The company is also a major force in cloud services through its AWS division, which offers on-demand solutions such as computing power, storage, databases, and machine learning tools. Although Amazon stock has rebounded from its April lows, its performance remains relatively slow, gaining just 4.5% year to date, compared with the S&P 500 Index's ($SPX) 7.3% advance over the same time frame. In terms of valuation, AMZN appears relatively expensive. Its price-to-sales ratio of 3.64 is well above the sector median of 0.98, indicating that investors are paying a premium. However, its price/earnings-to-growth (PEG) ratio of 0.51 points to potential undervaluation relative to its expected bottom-line growth, especially when compared to the sector average PEG of 0.78. Easing Tariffs and Improving Macro Outlook Morgan Stanley restored its 2026 EPS forecast for Amazon to $8, citing a 'significantly improved' macroeconomic outlook since mid‑April. The firm also raised its 2027 forecast, effectively reversing earlier cuts that had factored in potential punitive tariffs on Chinese imports. Morgan Stanley's team now judges the likelihood of extreme tariff measures disrupting Amazon's growth as 'much lower,' and views easing trade tensions as a catalyst for smoother execution across the retailer's core businesses. Tariff concerns weighed heavily on online retail earlier this year, but the latest note describes current pressures as 'manageable.' Unlike some peers, says the firm, Amazon can mitigate cost headwinds by diversifying its supply chain and fine‑tuning pricing strategies. Morgan Stanley specifically points to the improving tariff environment as a key driver behind its more optimistic outlook. AWS and AI Growth Catalysts A second pillar of Morgan Stanley's bullish view is Amazon's cloud and AI businesses. The firm wrote of an 'increased conviction in AWS acceleration' driven by the generative AI wave. Indeed, AWS has been Amazon's biggest profit engine, and it has only become more strategically vital as companies race to adopt AI tools. Notably, Amazon in Q1 announced new generative AI offerings on its Bedrock platform; for example, hosting Anthropic's Claude 3.7 Sonnet and Meta's (META) Llama 4 models for customers. Morgan Stanley highlighted partnerships like the one with AI startup Anthropic as concrete evidence of AWS's upside. It also cited the competitive cloud landscape, which includes Microsoft (MSFT) Azure's own AI push, as a validation of Amazon's strategy. Amazon's recent investment in AI infrastructure even includes custom hardware, as it revealed a specialized In-Row Heat Exchanger cooling system for Nvidia's (NVDA) latest AI chips, underscoring the mega-cap company's commitment to supporting compute-intensive workloads. Amazon Smashes Q1 Earnings Amazon's Q1 2025 results showed the business performing solidly, as Amazon reported net sales of $155.7 billion, which is up 9% from a year ago. All of Amazon's segments grew: North America retail revenue rose 8% to $92.9 billion; international revenue rose about 5% (8% excluding forex) to $33.5 billion; and AWS sales jumped 17% to $29.3 billion. The surge in AWS revenue was a key profit driver: AWS operating income in Q1 reached $11.5 billion, up from $9.4 billion a year ago. On the profitability front, net income soared to $17.1 billion, or $1.59 per share, from $10.4 billion ($0.98) in Q1 2024. That represents a huge step up in profit, even as the company continued to invest aggressively in new technology and logistics. However, AMZN slipped after earnings in response to a soft forecast. Looking ahead, investors will closely watch Amazon's Q2 results (due out after the close on July 31) for signs of resilience. The consensus projection is roughly $159–164 billion in sales with earnings around $1.30–$1.50 per share, but Morgan Stanley's call for easier tariffs and strong AWS momentum could help Amazon beat those estimates. What Does Wall Street Think About AMZN Stock? Backing Morgan Stanley's view, Wall Street analysts also remain bullish on Amazon's growth prospects. Among 54 analysts covering the stock, the consensus rating is 'Strong Buy,' with 47 assigning a 'Strong Buy,' six recommending a 'Moderate Buy,' and only one maintaining a 'Hold' rating. This bullish group has set an average price target of $249.85 for Amazon, implying a potential upside of about 9% from Monday's closing price. On the date of publication, Nauman Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on


Business Insider
an hour ago
- Business Insider
Market Woes Set Bearish Mood Ahead of Tesla's (TSLA) Q2 Earnings Call
Tesla's (TSLA) stock is once again on the rise ahead of its Q2 earnings report, scheduled for release after tomorrow's market close. With Q2 vehicle deliveries already disclosed earlier this month at 384,000 units, investor attention now shifts to profitability, strategic execution, and Tesla's ability to maintain its competitive edge. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. What's clear is that the days of unchecked, hyper-growth driven by EV manufacturing alone are behind us. Going forward, Tesla's success hinges on its ability to monetize emerging ventures like Robotaxi and Full Self-Driving (FSD). That said, the road ahead is filled with uncertainty—and at Tesla's current premium valuation, the margin for error is razor-thin. As a result, I remain Bearish on TSLA stock. Automotive Woes and Margin Compression First and foremost, market participants are seeking an update to the lifeblood of Tesla's business: its automotive segment. Due to increasing competition and a decline in demand for EVs, consensus estimates point to another challenging quarter for Tesla with double-digit decreases in year-over-year revenue. Tesla's market share is eroding globally. In fact, as of 2024, China-based BYD (BYDDF) is now the world's leading EV manufacturer by volume. This is especially a problem in China, which represents 21% of Tesla's revenue. Once a key growth engine for Tesla, vehicle sales in China are falling over 10% year-over-year. This is particularly worrisome when considering that the overall Chinese EV market is surging, which suggests that Tesla is losing market share. Secondly, Tesla faces a multi-front threat to its profitability. In the second quarter of last year, Tesla's automotive gross margin (ex-credits) was 18.3% and decreased to 16.3% in Q1 this year. Analysts anticipate further margin compression this quarter—and for good reason. Demand for Tesla's Model 3 and Model Y has weakened amid growing competition and more diverse offerings from rivals, as shown by production consistently outpacing deliveries. Like the broader EV industry, Tesla is also grappling with macroeconomic pressures. Elevated interest rates have made car payments less affordable, prompting buyers to opt for lower-priced, lower-margin models like the Model 3. In response to softening demand and rising competition, Tesla has introduced temporary price cuts, which are likely to weigh further on average selling prices and profit margins. TSLA Looks to Save the Day by Pivoting to Robotics & AI Tesla's lofty valuation—reflected in a P/E ratio of 181, more than 800% above the sector median—is largely built on investor confidence in its bold pivot toward artificial intelligence and robotics. The centerpiece of this AI narrative is Tesla's push for full autonomy, recently marked by the launch of a small fleet of around 20 robotaxis in Austin, Texas. While this marks a notable step, it's limited to a tightly geofenced area, making a broader rollout across major U.S. cities unlikely in the near term. At the helm, Elon Musk has gone on record to claim that 'millions of Teslas will be operating fully autonomously in the second half of next year [2026].' However, his track record includes many ambitious promises that were either delayed or never realized. Still, Tesla may unveil early proof-of-concept data from Austin in its earnings report, and potentially, reveal a firm timeline for launching its vast network of autonomous vehicles (AVs). Investors are also eyeing potential updates on Optimus, Tesla's humanoid robot initiative. Musk previously stated a goal of producing ~5,000-12,000 units this year and recently teased 'the most epic demo ever,' fueling speculation that the production-ready Optimus V3 may soon be revealed. However, skepticism remains high, given Musk's history of overpromising and the long road ahead for humanoid robotics. Realistically, Optimus remains a long-duration, high-risk R&D effort, with little chance of meaningful revenue contribution for years to come. Is TSLA Stock a Buy, Sell, or Hold? On Wall Street, TSLA carries a consensus Hold rating based on 13 Buy, 13 Hold, and eight Sell ratings in the past three months. TSLA's average stock price target of $299.52 implies a downside potential of almost 9% over the next 12 months. Earlier this week, Wall Street analyst Alexander Potter reiterated a Buy rating on TSLA with a price target of $400. Sandler believes concerns surrounding the impact of regulatory changes (EV tax credit) are overblown, stating, 'We think that while it's true that the U.S. government is committed to rescinding financial support for the EV and battery industries, Tesla will still book around $3 billion in credits this year, followed by $2.3 billion in 2026.' Tesla's Sluggish EV Growth and Unproven AI Ambitions Tesla's second-quarter earnings are likely to confirm what the market already suspects: its core EV business is losing momentum. With the company's lofty valuation now increasingly tied to its ambitions in AI and robotics, the focus is shifting from vision to execution. The market will soon demand real, near-term progress—not just bold promises. At the same time, Tesla must also defend its legacy automotive business, a tall order for any single company. Given its elevated valuation and the lack of immediate breakthroughs in its emerging tech initiatives, I'm staying Bearish for now. That said, for investors with a higher risk tolerance and a taste for short-term speculation, there's a case to be made. If Tesla falls short of expectations, it could trigger a sell-off, presenting both a selling opportunity in the near term and a potential buy-the-dip entry point for those who believe in Tesla's long-term dominance across EVs and robotics.


Medscape
2 hours ago
- Medscape
How Myeloma Plays Hide and Seek With CAR T Cells
TOPLINE: G protein-coupled receptor, class C, group 5, member D (GPRC5D) loss after chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) occurs through biallelic genetic inactivation and hypermethylation-driven epigenetic silencing. Among 10 patients who relapsed, eight showed GPRC5D loss, while two had mixed expression. METHODOLOGY: Researchers conducted whole-genome sequencing (WGS) and whole-genome bisulfite sequencing (WGBS) analysis on MM samples from 10 patients who relapsed after GPRC5D CAR T-cell therapy. Analysis included CD138+ MM cells isolated from bone marrow samples with purity exceeding 80%, with tumor samples sequenced at 100× coverage and matched normal samples at 30× coverage. Investigators performed targeted bisulfite sequencing to evaluate methylation status of GPRC5D regulatory regions across seven MM cell lines, with library construction and sequencing conducted by specialized institutes. Patient characteristics included median age of 57.5 years (range, 44-66 years), equal gender distribution, and 90% having high-risk cytogenetic abnormalities. TAKEAWAY: Genetic alterations were identified in three cases: one with homozygous deletion in GPRC5D gene, another with biallelic loss in regulatory regions, and a third with homozygous deletions in both TNFRSF17 and GPRC5D after sequential anti-B-cell maturation antigen and anti-GPRC5D CAR T-cell therapies. Multiple hypermethylation sites were present in transcriptional regulatory elements of GPRC5D gene in five posttreatment MM samples, with no genetic changes detected at GPRC5D locus in seven cases. GPRC5D expression showed inverse correlation with methylation levels in regulatory regions of MM cell lines, with azacitidine treatment inducing GPRC5D messenger RNA and protein expression in hypermethylated MM cell lines. All 10 patients achieved complete response or better as best response with median time to best response of 2.5 months (range, 0.5-15.3 months), though median time to disease progression was 15.9 months (range, 3.0-26.5 months). IN PRACTICE: 'Our findings highlight that biallelic genetic inactivation and hypermethylation-driven epigenetic silencing are key mechanisms contributing to GPRC5D loss and treatment resistance,' wrote the authors of the study. SOURCE: The study was led by Mingshan Niu, Blood Diseases Institute, Xuzhou Medical University in Xuzhou, China. It was published online in Blood. LIMITATIONS: According to the authors, the structural variant deletions on chromosomes may be missed by 100× WGS in patients with a clone size less than 20%. The limit of detection for quantitative polymerase chain reaction ranged from 16 to 50 copies per reaction, indicating sensitivity limitations of these detection methods. Additionally, genetic alterations in the GPRC5D locus could either be acquired after CAR T-cell therapy or selected from preexisting clones, necessitating more sensitive detection methods for dynamic monitoring. DISCLOSURES: The research received support from the National Natural Science Foundation of China (82270181) and the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (21KJA320005). The authors reported having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.